Significant progress has been made in the management of pulmonary hypertension (PH), and especially pulmonary arterial hypertnesion (PAH), over the last 3 decades. Recent advances in the diagnosis, risk stratification, and treatment of the disease have resulted in improved outcomes. However, patients with PAH continue to experience significant morbidity and mortality. Thus, continued research efforts are needed in order to develop risk stratification models and therapies that take into account more individualized patient-specific factors.